Second Genome

48 articles about Second Genome

• Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

  3/2/2022

  Second Genome platform discovered diverse and novel proteins for Bayer for potential development of next-generation insect-control products.

• Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)

  2/24/2022

  Second Genome yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD), and a briefing on SG-5-00455, the Company's development candidate for the treatment of IBD.

• Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of ECCO

  2/18/2022

  Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced preclinical data for SG-5-00455, the Company's development candidate.

• Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23

  2/14/2022

  Second Genome today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD) on Wednesday, February 23, 2022, from 12:00 – 1:00 p.m. EST.  

• Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

  2/10/2022

  Second Genome today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD).

• 

  BioSpace Movers & Shakers, Jan. 21

  1/21/2022

  Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. 

• Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

  1/19/2022

  Pharmaceutical leader brings over two decades of drug discovery and development in immunology and oncology.

• Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

  12/20/2021

  Second Genome today announced that the U.S. Patent and Trademark Office issued a U.S. patent, No. 11,174,293 B2, entitled, "Proteins for the Treatment of Epithelial Barrier Function Disorders."

• Second Genome Presents Preclinical Data at Crohn's & Colitis Foundation's® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

  11/18/2021

  Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn's & Colitis Foundation's IBD Innovate: Product Development in Crohn's & Colitis® virtual conference held November 18-19.

• Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways

  10/7/2021

  Second Genome presented preclinical data demonstrating that the Company's novel microbiome-derived peptide, SG-3-0020, can upregulate key co-stimulatory and checkpoint molecules on T cells.

• Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker

  9/23/2021

  Second Genome, leveraging machine learning capabilities and patient samples from studies led by VCU School of Medicine Professor Dr. Arun Sanyal, to identify microbiome signals to diagnose patients with NASH who have advanced fibrosis.

• Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy

  9/16/2021

  Second Genome presented preclinical data demonstrating that the Company's novel microbiome-derived peptide, SG-3-00802, can reverse resistance to anti-programmed death protein-1 therapy, illustrating that the microbiome directly interacts with the immune system to impact antitumor immunity.

• Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company's Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions

  8/23/2021

  Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, announced it has achieved a milestone in its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products.

• Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

  8/10/2021

  Second Genome presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD)

• Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

  8/5/2021

  Second Genome announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod.

• Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)

  6/22/2021

  Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight and AI workflows to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data demonstrating the use of its Multi-Technology Meta-Analysis Algorithm to identify microbial strains and peptides with therapeutic potential in inflammatory bowel disease patients.

• Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress

  6/9/2021

  Second Genome announced that the Company will present a demo of Odessa, its proprietary big data analytics software that is foundational to the Company's multi-disciplinary microbiome discovery and development platform, at the virtual Microbiome Data Congress on June 9–10, 2021.

• Second Genome to Present at the Jefferies Microbiome-Based Therapeutics Summit

  4/15/2021

   Second Genome, a tech-enabled biotechnology company that extracts microbial genetic insights to make transformational precision therapies and biomarkers, today announced that Karim Dabbagh , Ph.D., President and Chief Executive Officer, will present and participate in a fireside chat at the virtual Jefferies Microbiome-Based

• Second Genome To Present at Biotech Showcase Digital 2021 Conference

  1/11/2021

  Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13 th  Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39 th  Annual Healthcare Conference 2021.

• 

  Gilead Sciences, Second Genome Pair Up in Microbiome Research Pact Worth up to $1.5 Billion

  4/7/2020

  Gilead Sciences and Second Genome forged a four-year strategic collaboration that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.